美康生物：目前公司国际业务仍处于起步阶段

Core Viewpoint - The company, Meikang Bio (300439), is in the early stages of developing its international business, facing challenges related to market access and channel development [1] Group 1: International Business Development - The company has initiated a systematic construction of its international business since 2024, forming a specialized team for international registration and market expansion [1] - Initial results are expected in 2025 from market development efforts in emerging markets such as Russia, Turkey, the Philippines, and Vietnam [1] - The company aims to enhance its overall competitiveness in international markets by continuously strengthening team capabilities and accelerating product registration and certification in key markets [1]